Home › Employers › Glade Run Medical Associates, Inc.
Glade Run Medical Associates, Inc.: H-1B salaries and sponsorship
Glade Run Medical Associates, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $487,496.
Does Glade Run Medical Associates, Inc. sponsor H-1B visas?
Glade Run Medical Associates, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Nov 4, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Staff Urologist | 2 | $524,992 |
| Director of Outcome Research, Chief of the Dept of Urology | 1 | $450,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 1 | $450,000 |
| FY2025 | 2 | $524,992 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Staff Urologist | $524,992 part-time · Level IV | Kittanning, PA | Nov 4, 2024 | Dec 1, 2024 | Certified |
| Staff Urologist | $524,992 Level IV | Kittanning, PA | Oct 24, 2024 | Dec 1, 2024 | Certified |
| Director of Outcome Research, Chief of the Dept of Urology | $450,000–$550,000 Level IV | Kittanning, PA | Dec 28, 2020 | Mar 1, 2021 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).